Free Newsletter
Japanese R&D team targets next gen flu jabs
Investigators in Japan have designed a new vaccine that has been effective in animal tests against multiple strains of influenza, including varieties of the dread bird flu. Using a peptide derived from influenza virus that carries an antigen on the surface that triggers an immune response, the researchers noted that the vaccine worked on the inside of cells, rather than the surface. That's a dramatic departure from the vaccines used today, which target the surface of cells. Those surfaces change as the virus mutates, making the vaccines ineffective to the emerging strains of influenza.
The researchers at the National Institute of Infectious Diseases say that their breakthrough could provide a new generation of flu vaccines able to work across a broad spectrum of strains. They're now working on a vaccine that can be tested in humans.
- read the report from News-Medical
ALSO: Japanese investigators say they're seeing good results from a new bird flu vaccine that is sprayed up the nose rather than injected, a feature that could make it far easier to distribute in developing countries. Story
Related Articles:
Breakthrough on influenza vaccine. Report
Breakthrough reported in flu vaccine research. Report
Breakthrough in understanding mechanism of bird flu. Report
Experimental vaccines show efficacy against H5N1 viruses. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: